Comparison of intravaginal progesterone gel and intramuscular 17-alpha-hydroxyprogesterone caproate in luteal phase support


Creative Commons License

Şatır F., Toptas T., İnel M., Erman-Akar M., Taskin O.

EXPERIMENTAL AND THERAPEUTIC MEDICINE, cilt.5, sa.6, ss.1740-1744, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5 Sayı: 6
  • Basım Tarihi: 2013
  • Doi Numarası: 10.3892/etm.2013.1049
  • Dergi Adı: EXPERIMENTAL AND THERAPEUTIC MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1740-1744
  • Anahtar Kelimeler: intravaginal progesterone gel, 17-alpha-hydroxyprogesterone, luteal phase support, IN-VITRO FERTILIZATION, VAGINAL PROGESTERONE, CRINONE 8-PERCENT, MICRONIZED PROGESTERONE, GONADOTROPIN, CYCLES, SUPEROVULATION
  • Akdeniz Üniversitesi Adresli: Evet

Özet

The main objective of this study was to compare the pregnancy rates of intramuscular (IM) 17-alpha-hydroxyprogesterone caproate (17-HPC) and intravaginal (IV) progesterone gel administration in in vitro fertilization-embryo transfer (IVF-ET) cycles. The IM 17-HPC and IV progesterone groups included 632 (66.4%) and 320 (33.6%) women undergoing the first cycles of IVF-ET treatment, respectively. Multivariate analyses annotated for all potential confounders showed that the use of IV progesterone retained a predictive value for the total beta-human chorionic gonadotropin (hCG) positivity and clinical pregnancy rates [adjusted odds ratio (OR), 1.97; 95% confidence interval (CI), 1.28-3.03; P=0.002; and OR, 1.66; 95% CI, 1.07-2.60; P=0.03, respectively]. However, biochemical and on-going pregnancy rates did not differ significantly between the groups (OR, 1.85; 95% CI, 1.00-3.41; P=0.05; and OR, 1.43, 95% CI, 0.89-2.30; P=0.14, respectively). Luteal phase support (LPS) with IV progesterone gel in comparison with IM 17-HPC appears to be associated with higher clinical pregnancy rates in IVF-ET cycles. However, this benefit is clinically irrelevant in terms of on-going pregnancy outcomes.